Mark Lackner

Mark Lackner serves as Chief Scientific Officer at Firefly Bio since May 2025, focusing on Research and Development for novel degrader antibody conjugates. Additionally, Mark acts as a Scientific Advisor for Onc.AI since June 2021. Previously, Mark held the position of Chief Scientific Officer at Zentalis Pharmaceuticals from October 2022 to May 2025, overseeing all R&D efforts, including biomarker development for the WEE1 inhibitor azenosertib. Mark's experience also includes Chief Translational Officer and Head of Biomarker Strategy at IDEAYA Biosciences from May 2018 to October 2022, where responsibilities encompassed leading biology and translational science teams. Mark's early career included significant roles at Genentech, where a comprehensive approach to oncology biomarker development was established, along with prior positions at Exelixis and a postdoctoral fellowship at UC Berkeley. Mark holds a PhD in Developmental Biology from Stanford University, alongside postdoctoral training in Molecular Genetics and degrees in Biology from the University of Illinois Urbana-Champaign.